Revealing the cellular degradome by mass spectrometry analysis of proteasome-cleaved peptides

Cleavage products of the proteasome are profiled by mass spectrometry. Cellular function is critically regulated through degradation of substrates by the proteasome. To enable direct analysis of naturally cleaved proteasomal peptides under physiological conditions, we developed mass spectrometry ana...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature biotechnology 2018-12, Vol.36 (11), p.1110-1116
Hauptverfasser: Wolf-Levy, Hila, Javitt, Aaron, Eisenberg-Lerner, Avital, Kacen, Assaf, Ulman, Adi, Sheban, Daoud, Dassa, Bareket, Fishbain-Yoskovitz, Vered, Carmona-Rivera, Carmelo, Kramer, Matthias P, Nudel, Neta, Regev, Ifat, Zahavi, Liron, Elinger, Dalia, Kaplan, Mariana J, Morgenstern, David, Levin, Yishai, Merbl, Yifat
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Cleavage products of the proteasome are profiled by mass spectrometry. Cellular function is critically regulated through degradation of substrates by the proteasome. To enable direct analysis of naturally cleaved proteasomal peptides under physiological conditions, we developed mass spectrometry analysis of proteolytic peptides (MAPP), a method for proteasomal footprinting that allows for capture, isolation and analysis of proteasome-cleaved peptides. Application of MAPP to cancer cell lines as well as primary immune cells revealed dynamic modulation of the cellular degradome in response to various stimuli, such as proinflammatory signals. Further, we performed analysis of minute amounts of clinical samples by studying cells from the peripheral blood of patients with systemic lupus erythematosus (SLE). We found increased degradation of histones in patient immune cells, thereby suggesting a role of aberrant proteasomal degradation in the pathophysiology of SLE. Thus, MAPP offers a broadly applicable method to facilitate the study of the cellular-degradation landscape in various cellular conditions and diseases involving changes in proteasomal degradation, including protein aggregation diseases, autoimmunity and cancer.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt.4279